In experiments with lab-grown brain cells and mouse models, scientists at Johns Hopkins Medicine say they have discovered that a cell surface protein called Lag3 is not only a biological target for FDA-approved drugs that stimulate the immune system to attack cancer, but also may be a target for a drug designed to clean up “misfolded” Tau proteins linked to Alzheimer’s disease.